Lucid Diagnostics (NASDAQ:LUCD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Lucid Diagnostics (NASDAQ:LUCD) from a sell rating to a hold rating in a research note released on Saturday.

Several other analysts also recently issued reports on LUCD. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Monday, December 29th. Needham & Company LLC restated a “buy” rating and issued a $3.00 target price on shares of Lucid Diagnostics in a report on Thursday, March 26th. Finally, Ascendiant Capital Markets upped their target price on Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $3.94.

Lucid Diagnostics Trading Up 2.7%

LUCD stock opened at $1.15 on Friday. The firm has a market cap of $158.33 million, a PE ratio of -1.20 and a beta of 1.18. Lucid Diagnostics has a 1 year low of $0.95 and a 1 year high of $1.80. The company has a fifty day simple moving average of $1.29 and a 200 day simple moving average of $1.18.

Lucid Diagnostics (NASDAQ:LUCD) last posted its earnings results on Thursday, March 26th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The business had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $1.39 million. As a group, analysts forecast that Lucid Diagnostics will post -0.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Lucid Diagnostics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Centiva Capital LP bought a new position in shares of Lucid Diagnostics in the third quarter worth about $25,000. Sprott Inc. bought a new stake in Lucid Diagnostics during the 3rd quarter valued at approximately $25,000. SG Americas Securities LLC bought a new stake in Lucid Diagnostics during the 3rd quarter valued at approximately $26,000. Quadrature Capital Ltd acquired a new stake in Lucid Diagnostics in the 2nd quarter valued at approximately $29,000. Finally, Abel Hall LLC acquired a new stake in Lucid Diagnostics in the 4th quarter valued at approximately $33,000. 74.01% of the stock is owned by institutional investors and hedge funds.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.